| Certificates/Standards: | N; |
| Monthly Output: | Not provided |
| Regional: | Not provided |
| Packaging Information: | Not provided |
| Mode Of Payment: | Not provided |
| Delivery Lead Time: | Not provided |
| Main Sales Markets: | North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa |
| Sample Provided: | No |
| Sample Policy: | Not provided |
| Minimum Quantity: | Not provided |
The Bifidobacterium animalis subsp. lactis, BB-12® strain from Novonesis is the most documented Bifidobacterium in the world. The BB-12® strain has been described in around 400 scientific publications and supported by more than 200 publications describing studies in humans. Through scientific investigation, BB-12® has been associated with benefits in the areas of gastrointestinal health and immune health. The BB-12® strain has been tested in a range of people, from preterm babies through to the elderly, and across several health areas.
The world’s most documented probiotic strain. Since 1985, Lacticaseibacillus rhamnosus, LGG® has been the subject of more than 2,000 scientific publications, including 300 publications of human studies. LGG® has been used worldwide since 1990 as an ingredient in food and dietary supplements with no safety issues. This wealth of clinical documentation demonstrates the strain’s benefits and safety across life stages and health areas, from new-borns1, children, pregnant women, adult and the elderly.